spacer
home > epc > autumn 2008 > lifecycle conundrum
PUBLICATIONS
European Pharmaceutical Contractor

Lifecycle Conundrum

The pharmaceutical industry has entered a period of evolution and the next five to 10 years are certainly set to be interesting. Undoubtedly these are challenging times for the traditional model of large pharmaceutical companies, where each have a handful of major blockbuster products which, in turn, help to propagate the next round of R&D, whilst also returning a healthy profit on investment. With the recent decline in pipeline products passing through Phase III trials, it is an ageing product portfolio which is sustaining R&D.

These older products are soon to be open to legitimate generic competition and concurrently there has been a large increase in the number of specialised and generic companies bringing products rapidly to market, increasing the level of competition in the sector. Counterbalanced against both branded and generic medicines has been the explosion in counterfeits flooding the market, aided by the global expansion of the internet and direct consumer marketing.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Claire Madden-Smith is the Commercial Director at Molecular Profiles, a CRO providing advanced analysis, consultancy and formulation support to the pharmaceutical and biopharmaceutical industry. Claire completed her PhD in Physical Chemistry in 1998 and joined Molecular Profiles in 2001, providing advanced analysis and testing for development, manufacturing and intellectual property issues. Claire has presented extensively around the globe on analysis and understanding of drug delivery systems and is currently the Chair of the Marketing Committee of the Controlled Release Society and a committee member of the Material Science Focus Group of the British Academy of Pharmaceutical Sciences.
spacer
Dr Claire Madden-Smith
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

e-tools enhance clinical trial performance

e-novex

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement